This article is more than 5 years old. Information may no longer be current.

Company initiates warfarin sodium recall

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bristol-Myers Squibb has initiated a voluntary recall of one lot of warfarin sodium 5 mg tablets, according to an FDA press release.

A single tablet from a returned bottle was tested and found to have a higher potency than expected. The lot number of warfarin (Coumadin) in question is 9H49374A. The expiration date on the lot is Sept. 30, 2012.

The FDA recommends that patients in possession of these warfarin tablets should not interrupt therapy, but should consult their pharmacist. If the tablets are from the affected lot, they are advised to consult their physician. Warfarin sodium is prescribed as treatment for the prevention of blood clots. Too much of the active ingredient could result in excessive bleeding, according to the release.

Health care professionals are encouraged to report adverse events to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program.

Follow HemOncToday.com on Twitter.